• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

腹泻相关性溶血尿毒综合征的长期肾脏预后:一项系统评价、荟萃分析和元回归分析

Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression.

作者信息

Garg Amit X, Suri Rita S, Barrowman Nick, Rehman Faisal, Matsell Doug, Rosas-Arellano M Patricia, Salvadori Marina, Haynes R Brian, Clark William F

机构信息

Division of Adult and Pediatric Nephrology, University of Western Ontario, London, Canada.

出版信息

JAMA. 2003 Sep 10;290(10):1360-70. doi: 10.1001/jama.290.10.1360.

DOI:10.1001/jama.290.10.1360
PMID:12966129
Abstract

CONTEXT

The long-term renal prognosis of patients with diarrhea-associated hemolytic uremic syndrome (HUS) remains controversial.

OBJECTIVES

To quantify the long-term renal prognosis of patients with diarrhea-associated HUS and to identify reasons for different estimates provided in the literature.

DATA SOURCES

We searched MEDLINE and Experta Medica (EMBASE) bibliographic databases and conference proceedings, and we contacted experts until February 2003. We also searched the Institute for Scientific Information index and reference lists of all studies that fulfilled our eligibility criteria. The search strategy included the terms hemolytic-uremic syndrome, purpura, thrombotic thrombocytopenic, Escherichia coli O157, longitudinal studies, kidney diseases, hypertension, and proteinuria

STUDY SELECTION

Any study that followed up 10 or more patients with primary diarrhea-associated HUS for at least 1 year for renal sequelae.

DATA EXTRACTION

Two authors independently abstracted data on study and patient characteristics, renal measures, outcomes, and prognostic features. Disagreements were resolved by a third author or by consensus.

DATA SYNTHESIS

Forty-nine studies of 3476 patients with a mean follow-up of 4.4 years (range, 1-22 years at last follow-up) from 18 countries, 1950 to 2001, were summarized. At the time of recruitment, patients were aged 1 month to 18 years. In the different studies, death or permanent end-stage renal disease (ESRD) ranged from 0% to 30%, with a pooled incidence of 12% (95% confidence interval [CI], 10%-15%). A glomerular filtration rate lower than 80 mL/min per 1.73 m2, hypertension, or proteinuria was extremely variable and ranged from 0% to 64%, with a pooled incidence of 25% (95% CI, 20%-30%). A higher severity of acute illness was strongly associated with worse long-term prognosis. Studies with a higher proportion of patients with central nervous system symptoms (coma, seizures, or stroke) had a higher proportion of patients who died or developed permanent ESRD at follow-up (explaining 44% of the between-study variability, P =.01). Studies with a greater proportion of patients lost to follow-up also described a worse prognosis (P =.001) because these patients were typically healthier than those followed up. One or more years after diarrhea-associated HUS, patients with a predicted creatinine clearance higher than 80 mL/min per 1.73 m2, no overt proteinuria, and no hypertension appeared to have an excellent prognosis.

CONCLUSIONS

Death or ESRD occurs in about 12% of patients with diarrhea-associated HUS, and 25% of survivors demonstrate long-term renal sequelae. Patients lost to follow-up contribute to worse estimates in some studies. The severity of acute illness, particularly central nervous system symptoms and the need for initial dialysis, is strongly associated with a worse long-term prognosis.

摘要

背景

腹泻相关性溶血尿毒综合征(HUS)患者的长期肾脏预后仍存在争议。

目的

量化腹泻相关性HUS患者的长期肾脏预后,并找出文献中不同评估结果的原因。

数据来源

我们检索了MEDLINE和医学专家数据库(EMBASE)的文献数据库及会议论文集,并在2003年2月前与专家进行了联系。我们还检索了科学信息研究所的索引以及所有符合我们纳入标准的研究的参考文献列表。检索策略包括以下术语:溶血尿毒综合征、紫癜、血栓性血小板减少性紫癜、大肠杆菌O157、纵向研究、肾脏疾病、高血压和蛋白尿。

研究选择

任何对10例或更多原发性腹泻相关性HUS患者进行至少1年肾脏后遗症随访的研究。

数据提取

两位作者独立提取有关研究和患者特征、肾脏指标、结局及预后特征的数据。分歧由第三位作者解决或通过协商一致解决。

数据综合

总结了1950年至2001年来自18个国家的3476例患者的49项研究,平均随访4.4年(最后一次随访范围为1至22年)。入组时患者年龄为1个月至18岁。在不同研究中,死亡或永久性终末期肾病(ESRD)的发生率在0%至30%之间,合并发生率为12%(95%置信区间[CI],10% - 15%)。肾小球滤过率低于80 mL/min/1.73 m²、高血压或蛋白尿的发生率差异极大,在0%至64%之间,合并发生率为25%(95% CI,20% - 30%)。急性疾病的严重程度越高,长期预后越差。中枢神经系统症状(昏迷、癫痫发作或中风)患者比例较高的研究中,随访时死亡或发生永久性ESRD的患者比例也较高(解释了研究间差异的44%,P = 0.01)。失访患者比例较高的研究也显示预后较差(P = 0.001),因为这些患者通常比接受随访的患者更健康。腹泻相关性HUS发生1年或更长时间后,预测肌酐清除率高于80 mL/min/1.73 m²、无明显蛋白尿且无高血压的患者预后似乎良好。

结论

腹泻相关性HUS患者中约12%发生死亡或ESRD,25%的幸存者有长期肾脏后遗症。在一些研究中,失访患者导致了较差的评估结果。急性疾病的严重程度,尤其是中枢神经系统症状和初始透析的需求,与较差的长期预后密切相关。

相似文献

1
Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression.腹泻相关性溶血尿毒综合征的长期肾脏预后:一项系统评价、荟萃分析和元回归分析
JAMA. 2003 Sep 10;290(10):1360-70. doi: 10.1001/jama.290.10.1360.
2
Sertindole for schizophrenia.用于治疗精神分裂症的舍吲哚。
Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2.
3
Comparison of cellulose, modified cellulose and synthetic membranes in the haemodialysis of patients with end-stage renal disease.纤维素、改性纤维素和合成膜在终末期肾病患者血液透析中的比较。
Cochrane Database Syst Rev. 2001(3):CD003234. doi: 10.1002/14651858.CD003234.
4
Systematic review on urine albumin testing for early detection of diabetic complications.关于尿白蛋白检测用于早期发现糖尿病并发症的系统评价。
Health Technol Assess. 2005 Aug;9(30):iii-vi, xiii-163. doi: 10.3310/hta9300.
5
Surgical interventions for treating extracapsular hip fractures in older adults: a network meta-analysis.老年人髋关节囊外骨折的手术干预:一项网络荟萃分析。
Cochrane Database Syst Rev. 2022 Feb 10;2(2):CD013405. doi: 10.1002/14651858.CD013405.pub2.
6
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.嵌合抗原受体 (CAR) T 细胞疗法治疗复发或难治性弥漫性大 B 细胞淋巴瘤患者。
Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2.
7
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
8
Surgical interventions for treating intracapsular hip fractures in older adults: a network meta-analysis.老年人囊内型髋部骨折的手术治疗:网状荟萃分析。
Cochrane Database Syst Rev. 2022 Feb 14;2(2):CD013404. doi: 10.1002/14651858.CD013404.pub2.
9
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
10
Blue-light filtering intraocular lenses (IOLs) for protecting macular health.用于保护黄斑健康的蓝光滤过型人工晶状体
Cochrane Database Syst Rev. 2018 May 22;5(5):CD011977. doi: 10.1002/14651858.CD011977.pub2.

引用本文的文献

1
Interventions for preventing diarrhoea-associated haemolytic uraemic syndrome.预防腹泻相关性溶血尿毒综合征的干预措施。
Cochrane Database Syst Rev. 2025 Apr 25;4(4):CD012997. doi: 10.1002/14651858.CD012997.pub3.
2
Inhibition of tumour necrosis factor alpha by Etanercept attenuates Shiga toxin-induced brain pathology.依那西普对肿瘤坏死因子α的抑制作用减轻了志贺毒素诱导的脑部病变。
J Neuroinflammation. 2025 Feb 7;22(1):33. doi: 10.1186/s12974-025-03356-z.
3
Long-term health outcomes of Shiga toxin-producing Escherichia coli O157 (STEC O157) infection and STEC-associated haemolytic uraemic syndrome (STEC-HUS), Wales, 1990-2020.
1990 - 2020年威尔士产志贺毒素大肠杆菌O157(STEC O157)感染及STEC相关溶血尿毒综合征(STEC - HUS)的长期健康结局
Pediatr Nephrol. 2025 Feb 4. doi: 10.1007/s00467-024-06640-x.
4
Open-label, controlled, phase 2 clinical trial assessing the safety, efficacy, and pharmacokinetics of INM004 in pediatric patients with Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome.一项开放标签、对照的2期临床试验,评估INM004在产志贺毒素大肠杆菌相关溶血尿毒综合征儿科患者中的安全性、有效性和药代动力学。
Pediatr Nephrol. 2025 Jun;40(6):1983-1995. doi: 10.1007/s00467-024-06583-3. Epub 2024 Nov 12.
5
Ultrasound analysis of different forms of hemolytic uremic syndrome in children.儿童不同形式溶血尿毒综合征的超声分析
Front Pediatr. 2024 Oct 23;12:1433812. doi: 10.3389/fped.2024.1433812. eCollection 2024.
6
Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023.《2023年慢性腹泻循证临床指南》
Digestion. 2024;105(6):480-497. doi: 10.1159/000541121. Epub 2024 Aug 28.
7
Long-Term Kidney Outcomes after Pediatric Acute Kidney Injury.儿童急性肾损伤后的长期肾脏结局
J Am Soc Nephrol. 2024 Nov 1;35(11):1520-1532. doi: 10.1681/ASN.0000000000000445. Epub 2024 Jul 17.
8
A better future for children with STEC-hemolytic uremic syndrome: news from Argentina.感染产志贺毒素大肠杆菌溶血性尿毒综合征患儿的美好未来:来自阿根廷的消息
Pediatr Nephrol. 2025 Jan;40(1):1-2. doi: 10.1007/s00467-024-06429-y. Epub 2024 Jul 2.
9
Pediatric acute kidney injury and adverse health outcomes: using a foundational framework to evaluate a causal link.儿科急性肾损伤与不良健康结局:使用基础框架评估因果关系。
Pediatr Nephrol. 2024 Dec;39(12):3425-3438. doi: 10.1007/s00467-024-06437-y. Epub 2024 Jul 1.
10
Lung Ultrasound to Evaluate Fluid Status and Optimize Early Volume-Expansion Therapy in Children with Shiga Toxin-Producing Escherichia Coli-Haemolytic Uremic Syndrome: A Pilot Study.肺超声评估产志贺毒素大肠杆菌 - 溶血尿毒综合征患儿的液体状态并优化早期容量扩张治疗:一项初步研究
J Clin Med. 2024 May 21;13(11):3024. doi: 10.3390/jcm13113024.